UniProt Q8NG66 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dabrafenib | 92.1% | 7.9% | 94.74 | 0.633 |
| 2 | Vemurafenib | 64.0% | 36.0% | 96.49 | 0.598 |
| 3 | Dasatinib | 47.0% | 53.0% | 87.97 | 0.699 |
| 4 | Repotrectinib | 45.4% | 54.6% | 84.21 | 0.608 |
| 5 | Fedratinib | 22.8% | 77.2% | 96.21 | 0.576 |
| 6 | Pexidartinib | 22.6% | 77.4% | 99.49 | 0.631 |
| 7 | Asciminib | 19.7% | 80.3% | 100.00 | 0.602 |
| 8 | Futibatinib | 16.5% | 83.5% | 98.48 | 0.718 |
| 9 | Crizotinib | 14.5% | 85.5% | 91.39 | 0.581 |
| 10 | Darovasertib | 14.1% | 85.9% | 96.99 | 0.719 |
| 11 | Quizartinib | 13.8% | 86.2% | 99.50 | 0.737 |
| 12 | Sirolimus | 12.3% | 87.7% | 100.00 | 0.708 |
| 13 | Umbralisib | 12.0% | 88.0% | 98.74 | 0.670 |
| 14 | Lapatinib | 11.9% | 88.1% | 99.25 | 0.616 |
| 15 | Pacritinib | 11.5% | 88.5% | 88.64 | 0.452 |
| 16 | Gefitinib | 11.4% | 88.6% | 99.25 | 0.650 |
| 17 | Alpelisib | 11.1% | 88.9% | 97.22 | 0.720 |
| 18 | Abemaciclib | 11.1% | 88.9% | 91.48 | 0.563 |
| 19 | Lorlatinib | 10.6% | 89.4% | 97.24 | 0.694 |
| 20 | Neratinib | 9.3% | 90.7% | 93.18 | 0.597 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.00
- Epithelial log2(TPM+1): 1.64
- Fold change: 0.37
- Status: No significant change
High-confidence drugs
- Dabrafenib — inh 92.1% · KISS 34.12
- Vemurafenib — inh 64.0% · KISS 3.23
- Dasatinib — inh 47.0% · KISS -14.02
Selectivity landscape vs inhibition on NEK11
Each point is one of the 92 approved drugs; color = inhibition % on NEK11.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…